Stock Trading Canary← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Koh Bong Y
10% Owner
Identity: SEC owner CIK matched through an unambiguous cached owner-name crosswalk · Reporting-owner CIK: 0001615979
Purchase history
- Companies traded
- 3
- Purchases · 12M
- 3
- Purchases · 24M
- 8
- Average purchase
- $5.4M
- Median purchase
- $805.9K
- Gross purchase value
- $43.3M
Companies: KalVista Pharmaceuticals, Inc. | Lycia Therapeutics, Inc. | Oruka Therapeutics, Inc.
8 SEC accession(s) · 8 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-11-04 | Lycia Therapeutics, Inc. | LYCA | 10% Owner | $223.8K | Open filing |
| 2026-10-30 | Lycia Therapeutics, Inc. | LYCA | 10% Owner | $644.7K | Open filing |
| 2026-10-27 | Lycia Therapeutics, Inc. | LYCA | 10% Owner | $37.7M | Open filing |
| 2025-04-11 | KalVista Pharmaceuticals, Inc. | KALV | 10% Owner | $235.5K | Open filing |
| 2025-02-27 | Oruka Therapeutics, Inc. | ORKA | 10% Owner | $1.4M | Open filing |
| 2025-02-14 | KalVista Pharmaceuticals, Inc. | KALV | 10% Owner | $1.5M | Open filing |
| 2025-02-11 | KalVista Pharmaceuticals, Inc. | KALV | 10% Owner | $967.1K | Open filing |
| 2025-02-03 | KalVista Pharmaceuticals, Inc. | KALV | 10% Owner | $621.6K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 1/6
- Large purchase ≥ $100k
- 8/8
- Cluster buying · 15D
- 8/8
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.